Posted by Michael Wonder on 01 Feb 2018
NHS England takes charge on market access
1 February 2018 - Today sees patients gain full NHS access to breast cancer drug Perjeta, a full six years on from its initial review by NICE.
The increasing power of NHS England to negotiate deals direct with the pharmaceutical industry is helping to unlock UK market access for many new drugs – but just how far will it take this new role?
NHS England has taken on several important functions from the Department of Health in the last year, and has created a new Commercial Medicines Unit to engage directly with industry.
